-
Abstract Number: PB1102
UK NEQAS (Blood Coagulation) Genetics of Heritable Bleeding and Thrombotic disorders programme – a review of External Quality Assessment (EQA) Scheme exercises 2021.
-
Abstract Number: PB1245
Uncommon arterial and venous thrombotic complications in Bernard Soulier Syndrome and Glanzmann Thrombasthenia patients
-
Abstract Number: PB0896
Under increased platelet turnover large and small platelets are produced simultaneously
-
Abstract Number: PB0735
Understanding fate of circulating von Willebrand factor following interaction with polymorphonuclear leukocytes
-
Abstract Number: OC 68.3
Understanding the role of the renin-angiotensin system in endothelial senescence in chronic obstructive pulmonary disease
-
Abstract Number: PB0866
Unidentified pre-analytical factors influence measures of platelet reactivity in the Framingham Heart Study
-
Abstract Number: OC 22.4
Unique humanized mouse models of von Willebrand disease to implement the need for innovative therapeutic strategies
-
Abstract Number: VPB0740
Unique Protein Profiles with Inflammatory, Complement, and Endothelial Activation Signature Identified Patients with Alcohol-Associated and Non-Alcoholic Steatohepatitis Associated Cirrhosis
-
Abstract Number: OC 70.3
Unmet Medical Needs in Patient-Reported Outcomes and Sports Activity in People with Haemophilia A/B with or without Inhibitors: Historical Data from Patients Entering a Non-Interventional Study
-
Abstract Number: VPB0613
Unraveling The Pathophysiological Role of Angiostatin in COVID-19
-
Abstract Number: PB0657
Up to 6 years of once-weekly prophylactic dosing of nonacog beta pegol (N9-GP) was associated with high adherence, with a low incidence of spontaneous bleeds in children with hemophilia B
-
Abstract Number: PB0999
Update in The Management Tools of Thrombotic Thrombocytopenic Purpura(TTP) As One of the Rare Hematological Disorders with A Highlight On the Cost Value of Such Diseases
-
Abstract Number: OC 73.1
Updated Main Study Period and Long-Term Extension (LTE) Results With Oral Bruton Tyrosine Kinase Inhibitor Rilzabrutinib in Immune Thrombocytopenia (ITP)
-
Abstract Number: PB0521
Use of antithrombotic agents for the prevention of coronary and peripheral arterial events in patients with end-stage kidney disease on hemodialysis: Prospective results of the VIVALDI study
-
Abstract Number: VPB0979
Use of D-dimer for the exclusion of new pulmonary embolism in anticoagulated patients: A multicenter retrospective study
-
Abstract Number: VPB0115
Use of direct oral anticoagulants (DOACs) in prevention or treatment of Pulmonary Embolism (PE) associated with COVID-19 pneumonia in ambulatory patients: experience of an Argentine center
-
Abstract Number: PB0560
Use of heparin-calibrated assays to estimate anti-factor Xa activity of factor Xa inhibitors (FXaI): a literature correlation analysis
-
Abstract Number: PB0983
Use of prothrombin complex concentrates in severe liver disease: in vitro dose effects on haemostasis parameters: COPIH Study
-
Abstract Number: PB1415
Use of recombinant von Willebrand factor concentrate for peri-partum haemostatic management of women with type 2 VWD; a case series
-
Abstract Number: PB0344
Use of romiplostim in paediatric patients with immune thrombocytopenic purpura (ITP)
-
Abstract Number: PB0393
Use of spectral flow cytometry to immunophenotype platelets
-
Abstract Number: PB0084
Use of Telemedicine for Outpatients’ Follow-up during the COVID-19 Pandemic: the Experience of an Italian Pediatric Center of Hemostasis and Thrombosis
-
Abstract Number: PB0833
Usefulness of in-silico prediction tools in the analysis of VWF genetic variants.
-
Abstract Number: PB0702
Usefulness of rotational plasma thromboelastometry in severe inherited FXIII deficiency
-
Abstract Number: VPB0209
Usefulness of the human-factor based chromogenic substrate assay for evaluating coagulability of Emicizumab
-
Abstract Number: PB0776
Using a multi-omics approach to understand endothelial dysregulation of platelet activation in inflammatory conditions
-
Abstract Number: VPB0282
Using an EMR patient portal for warfarin self-management: exploring children and families’ experiences
-
Abstract Number: PB0831
Using GP1bM Activity (VWF:GPIbM) versus Ristocetin Cofactor Activity (VWF:RCo) in von Willebrand Factor Panels
-
Abstract Number: PB1331
Using natural language processing to diagnose venous thromboembolism: A systematic review
-
Abstract Number: VPB0575
USP Standardized Mixtures of Bovine, Ovine and Porcine Heparin Demonstrate Comparable Biologic Effects to Referenced Single Sourced Heparins and May be Interchangeable
-
Abstract Number: PB1069
Utility of ISTH Bleeding Assessment Tool in identifying bleeders and predicting bleeding severity in inherited primary and secondary haemostasis defects
-
Abstract Number: VPB0898
Utilizing a Quartz Crystal Microbalance with dissipation (QCM-D) to Study Platelet NO-Signalling Under Flow Conditions
ISTH 2022 Congress
July 9-13, 2022. London, England, UK.